Printer Friendly

Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting.

SEATTLE, April 24 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced the following data presentations taking place at the American Urological Association's (AUA) Annual Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data webcast conference call:
 -- April 28, 2009, 2:20 p.m. CDT - "A randomized, double-blind,
 placebo-controlled, multi-center, phase III trial of sipuleucel-T in
 men with metastatic, androgen independent prostatic adenocarcinoma
 (AIPC)." AUA Late-Breaking Science Forum to be held from 1:00 p.m. to
 2:30 p.m. CDT. Room W375 at McCormick Place
 -- April 28, 2009, 10:30 a.m. to 12:30 p.m. CDT - Abstract #1408:
 "Preclinical Evaluation of the TRPM8 Ion Channel Agonist D-3263 for
 Benign Prostatic Hyperplasia." Poster presentation to occur in the
 Benign Prostatic Hyperplasia: Basic Research session. Room W375B at
 McCormick Place

 -- April 28, 2009, 4:30 p.m. CDT - IMPACT data webcast conference call

The IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study evaluated PROVENGE(R) (sipuleucel-T), Dendreon's investigational product candidate for men with advanced prostate cancer representing the first in a new class of active cellular immunotherapies specifically designed to engage the patient's own immune system against cancer. Dendreon announced last week that the IMPACT trial met its primary endpoint of improving overall survival compared to a placebo control.

To access the live conference call, dial 1-877-675-4753 (domestic) or 719-325-4864 (international). The call also will be audio webcast and will be available from the Company's website at under the "Investor/Webcasts and Presentations" section. There will be a slide presentation to accompany the call, which will also be available on this section of the Dendreon website. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 (domestic) or 719-457-0820 (international); the conference ID number is 6483399. The replay will be available from 8:00 p.m. ET, April 28, 2009 until midnight April 29, 2009. In addition, the webcast will be archived for on-demand listening for 30 days at

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit

CONTACT: Jennifer Cook Williams, Investor Relations of Dendreon Corporation, +1-206-829-1500; or media, Katherine Stueland of WeissComm Partners, +1-312-608-0320,, for Dendreon Corporation

Web Site:
COPYRIGHT 2009 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 24, 2009
Previous Article:Neovasc Inc. Reports Year 2008 Financial Results.
Next Article:Champion Enterprises Reports First Quarter 2009 Results.

Related Articles
Dendreon Reports Preliminary D9902A Trial Data For Provenge in Patients With Advanced Prostate Cancer.
Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference.
Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference.
PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study.
Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia.
Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study.
Dendreon Reports First Quarter 2009 Financial Results.
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences.
Dendreon Reports Second Quarter 2009 Financial Results.
Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters